COMBINATIONS Russian patent published in 2025 - IPC A61K31/519 A61K31/437 A61K31/496 A61P35/02 

Abstract RU 2840819 C1

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and medicine, specifically to a method for treating a disease or condition, wherein said disease or condition is selected from the group, consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm. Method of treating a disease or condition, wherein said disease or condition is selected from the group consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm, wherein said method comprises administering a combination, the combination comprising an effective amount of compound (A) and an effective amount of compound (B) or a pharmaceutically acceptable salt thereof, wherein compound (A) has the following structure:

wherein R1 is hydrogen;

is selected from the group consisting of substituted , substituted and substituted , where ring B is substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, unsubstituted methyl and unsubstituted ethyl; R2 is ; m is 0 or 1; R3 is unsubstituted C1-C6 alkyl; X is selected from the group consisting of and ; Y is CH; and compound (B) is a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof; wherein the Bcl-2 inhibitor is selected from the group consisting of venetoclax (ABT-199) and navitoclax (ABT-263) or pharmaceutically acceptable salts of any of said.

EFFECT: method described above is more effective in treating said diseases or conditions as compared to the monotherapy.

16 cl, 4 dwg, 2 tbl

Similar patents RU2840819C1

Title Year Author Number
EGFR INHIBITOR COMPOUNDS 2017
  • Banker, Kevin Duejn
  • Khuan, Piter Tsinkhua
  • Abrakham, Sanni
  • Pinchman, Dzhozef Robert
  • Khopkins, Chad Deniel
  • Sli, Debora Khelen
RU2751341C2
COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF 2021
  • Feng, Yan
  • Li, Shiqiang
RU2829459C1
SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES 2019
  • Khuan, Piter, Tsinkhua
  • Banker, Kevin, Duejn
  • Boren, Brant, Klejton
  • Khegde, Saji, Gadzhanan
  • Lyu, Khuej
  • Unni, Aditya, Krishnan
  • Abrakham, Sanni
  • Khopkins, Chad, Deniel
  • Palival, Sunil
RU2812726C2
BENZAMIDE COMPOUNDS 2019
  • Pinchman, Dzhozef Robert
  • Khuan, Piter Tsinkhua
  • Banker, Kevin Duejn
  • Sit, Rakesh Kumar
  • Samatar, Akhmed Abdi
RU2801647C2
SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS 2020
  • Tan, Khaokhan
  • Lyu, Tsikhun
  • Lyu, Bin
  • Li, Chzhifu
  • Van, Syanlun
  • Chzhou, Tszuven
  • Chzhan, Vejpen
  • Van, Yunlin
  • Chzhou, Chenlin
  • Gao, Yujvej
  • Tszyan, Likhua
  • Lyu, Yansin
  • Tszou, Tszunyao
  • Lin, Shu
  • Yuj, Kaj
  • Li, Tunshuan
  • Chzhao, Sindun
  • Van, Vejbo
RU2824583C2
3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF 2021
  • Zhao Chuanwu
  • Zhang Yan
  • Yang Jinlu
  • Zhang Li
  • Zhang Xuejiao
  • Cui Shuxiang
  • Guo Qian
RU2825312C1
CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PHARMACEUTICAL USE THEREOF 2021
  • Huang Jian
  • Zhu Lingjian
  • Zou Yang
  • Zhang Cili
RU2831014C1
SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXANE-2-YL)PYRAZOLO[1.5-A]PYRIMIDINE AND IMIDAZO[1.2-B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS 2019
  • Lyu, Khunbin
  • Tan, Khaokhan
  • Khe, Chensi
  • Van, Syanlun
  • Lyu, Tsikhun
  • Li, Chzhifu
  • Chzhou, Tszuven
  • Gao, Yujvej
  • Tszyan, Likhua
  • Linkhu, Li
  • Lin, Shu
  • Chzhao, Sindun
  • Van, Vejbo
RU2781618C2
CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE 2016
  • Bradner Dzhejms I.
  • Tsi Tszyun
  • Tanaka Minoru
  • Bakli Dennis
RU2750164C2
CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS 2020
  • Chzhi, Lin
RU2836016C2

RU 2 840 819 C1

Authors

Samatar, Akhmed Abdi

Li, Tszyali

Izadi, Khuman

Khuan, Piter Tsinkhua

Pinchman, Dzhozef Robert

Boren, Brant Klejton

Banker, Kevin Duejn

Donejt, Fernando

Dates

2025-05-28Published

2020-12-16Filed